Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Alexion Broadens and Strengthens its Executive Leadership Team

Published: Friday, April 26, 2013
Last Updated: Friday, April 26, 2013
Bookmark and Share
Company has expanding global mission to develop and commercialize life transforming therapies for patients with disorders that are severe, life-threatening, and ultra-rare.

Stephen Squinto, Ph.D., co-founder of Alexion, is being promoted to the newly created position of Executive Vice President, Chief Global Operations Officer. Martin Mackay, Ph.D. will be joining Alexion as Executive Vice President, Global Head of R&D, and Saqib Islam, J.D. has joined Alexion as Senior Vice President, Chief Strategy and Portfolio Officer. All three executives will report directly to Leonard Bell, M.D., Chief Executive Officer of Alexion.

The arrivals of Dr. Mackay and Mr. Islam will help to broaden Alexion’s portfolio of transformative ultra-orphan therapeutic candidates and accelerate the development of these candidates into approved products. The promotion of Dr. Squinto to his new position will support these initiatives, and also improve and expand critical processes in manufacturing, quality and corporate project management.

Growing to Serve More Patients, with More Disorders, in More Countries

Alexion currently serves patients in nearly 50 countries with Soliris® (eculizumab), the Company’s first approved product. Soliris is approved for patients with paroxysmal nocturnal hemoglobinuria (PNH) in the US, European Union, Japan and other territories as the first and only treatment indicated for this debilitating and life-threatening ultra-rare blood disease. Soliris is also approved for patients with atypical hemolytic uremic syndrome (aHUS) in the US and European Union as the first and only treatment indicated for this life-threatening and ultra-rare, genetic disease. As it continues the global introductions of Soliris in PNH and aHUS, the Company is developing the most robust pipeline in its history, with five highly innovative therapeutic candidates at various stages of development across nine severe and life-threatening disorders that are also ultra-rare.

Stephen Squinto, Ph.D.
Dr. Squinto, co-founder of Alexion along with Dr. Bell, has helped to grow the Company from a start-up to a global organization with 1,500 employees around the world. Dr. Squinto continues to serve as a key member of the executive leadership team, having risen to Executive Vice President and Head of R&D in 2007, and subsequently leading the development of Soliris through its approval in aHUS. Most recently, Dr. Squinto has driven the expansion of Alexion’s R&D pipeline to now comprise five highly innovative therapeutic candidates. In his new position of Chief Global Operations Officer, Dr. Squinto will increasingly focus his activities on leadership of the Company’s critical technical operations and quality organizations. Dr. Squinto will commence his new duties at Alexion in mid-May.

“Steve’s deep experience, strong technical background and excellent leadership skills, position him well to lead the critical expansions in our global manufacturing and quality organizations,” said Dr. Bell. “Additionally, Steve’s leadership in the development of a corporate project management organization will serve as a critical underpinning for our global growth across many vital functions and projects.”

Martin Mackay, Ph.D.
Dr. Mackay brings to Alexion more than 30 years of experience in drug discovery and development on a global scale. In his position, Dr. Mackay will focus on continuing to build and improve Alexion’s global research and development organization with a goal of accelerating the simultaneous development of multiple drug candidates in debilitating and life-threatening ultra-rare disorders across a range of therapeutic areas. Most recently, Dr. Mackay served as President, Research and Development at AstraZeneca, reporting directly to the CEO, where he led all R&D functions on a global basis, including discovery research, clinical development, regulatory affairs and key related R&D functions. Prior to AstraZeneca, Dr. Mackay held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D, where he reported to the CEO and Chairman, overseeing all aspects of discovery and development of therapies across nine therapeutic areas. Earlier in his career, Dr. Mackay worked in the CIBA organization (now Novartis) and held positions within academia. He received his Ph.D. in molecular genetics from the University of Edinburgh, Scotland. Dr. Mackay will join Alexion in mid-May.

“I am excited to be joining Alexion at a time when the company is developing the most robust pipeline in its history. With an exclusive focus on transformative therapies, we can bring hope to an increasing number of patients with a wide range of life-threatening ultra-rare disorders,” said Dr. Mackay.

“Martin’s passion to help patients, and his world-class experience in building and leading talented R&D organizations across multiple therapeutic areas, will help Alexion to reach the next levels in our mission to bring additional breakthrough therapies to individuals and families suffering from devastating and ultra-rare conditions,” said Dr. Bell.

Saqib Islam
Mr. Islam brings to Alexion 18 years of experience in global business management, with a focus on business development, strategic decision-making and planning, and capital markets. In his new position, he will focus on both executing our corporate growth strategies as well as contributing to our assessment and management of our global operations. Mr. Islam has an extensive background in the healthcare banking sector, having held positions of increasing responsibility in the investment banking divisions of Merrill Lynch, Morgan Stanley, and most recently, Credit Suisse Securities, where he served as Managing Director, Head of Healthcare and Diversified Industrials Capital Markets. Earlier in his career, at The Boston Consulting Group, Mr. Islam had provided strategic analysis and advice to client firms across diverse industry segments. Mr. Islam received his Bachelor’s degree from McGill University and his J.D. from Columbia Law School.

“Alexion offers an unmatched combination of a unique and highly respected track record within the ultra-orphan space, substantial global resources, and an entrepreneurial determination to serve even more patients with severe, ultra-rare disorders,” said Mr. Islam. “I look forward to helping Alexion to continue growing into a leadership position on the global healthcare stage.”

“Saqib’s experience within healthcare and across other key industries will be invaluable as we enter the next phase of leading the Alexion organization to maximize our opportunities to serve patients,” said Dr. Bell. “He will play a central role as we continue to grow our global organization to serve more patients with additional severe and ultra-rare disorders.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos